Literature DB >> 17453144

RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.

J-M Gallo1, W Noble, T Rodriguez Martin.   

Abstract

Tauopathies are a group of neurodegenerative diseases characterised by intracellular deposits of the microtubule-associated protein tau. The most typical example of a tauopathy is Alzheimer's disease. The importance of tau in neuronal dysfunction and degeneration has been demonstrated by the discovery of dominant mutations in the MAPT gene, encoding tau, in some rare dementias. Recent developments have shed light on the significance of tau phosphorylation and aggregation in pathogenesis. Furthermore, emerging evidence reveals the central role played by tau pre-mRNA processing in tauopathies. The present review focuses on the current understanding of tau-dependent pathogenic mechanisms and how realistic therapies for tauopathies can be developed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453144     DOI: 10.1007/s00018-007-6513-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  17 in total

1.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 2.  The role of CELF proteins in neurological disorders.

Authors:  Jean-Marc Gallo; Carl Spickett
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 3.  Targeting RNA-splicing for SMA treatment.

Authors:  Jianhua Zhou; Xuexiu Zheng; Haihong Shen
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

4.  RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site.

Authors:  Amar Kar; Kazuo Fushimi; Xiaohong Zhou; Payal Ray; Chen Shi; Xiaoping Chen; Zhiren Liu; She Chen; Jane Y Wu
Journal:  Mol Cell Biol       Date:  2011-02-22       Impact factor: 4.272

Review 5.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

6.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

7.  miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo.

Authors:  Pascal Y Smith; Julia Hernandez-Rapp; Francis Jolivette; Cynthia Lecours; Kanchan Bisht; Claudia Goupil; Veronique Dorval; Sepideh Parsi; Françoise Morin; Emmanuel Planel; David A Bennett; Francisco-Jose Fernandez-Gomez; Nicolas Sergeant; Luc Buée; Marie-Ève Tremblay; Frédéric Calon; Sébastien S Hébert
Journal:  Hum Mol Genet       Date:  2015-09-11       Impact factor: 6.150

Review 8.  RNA processing-associated molecular mechanisms of neurodegenerative diseases.

Authors:  Anna Y Tang
Journal:  J Appl Genet       Date:  2015-12-03       Impact factor: 3.240

9.  Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain.

Authors:  Boris Rogelj; Laura E Easton; Gireesh K Bogu; Lawrence W Stanton; Gregor Rot; Tomaž Curk; Blaž Zupan; Yoichiro Sugimoto; Miha Modic; Nejc Haberman; James Tollervey; Ritsuko Fujii; Toru Takumi; Christopher E Shaw; Jernej Ule
Journal:  Sci Rep       Date:  2012-08-28       Impact factor: 4.379

Review 10.  Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.

Authors:  Jianhua Zhou; Qingming Yu; Tie Zou
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.